RUNX1T1 and acute myeloid leukemia: We also found that 62.5% (15/24) of patients with CBF AML could still be detected with CBF MRD + after transplantation, with a median VAF of 0.011% (RUNX1-RUNX1T1: 0.010%, CBFβ-MYH11: 0.026%).